Express News | Amgen Inc : RBC Cuts Target Price to $360 From $362
Is There An Opportunity With Amgen Inc.'s (NASDAQ:AMGN) 49% Undervaluation?
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Viking Therapeutics a New Buy at B Riley on Lead Obesity Asset VK2735
Astrazeneca (AZN.US) and Amgen (AMGN.US) announced the domestic application for the subcutaneous injection of TSLP monoclonal antibody.
CDE's official website shows that astrazeneca (AZN.US) and amgen (AMGN.US) jointly submitted the marketing application for the TSLP monoclonal antibody Tezepelumab injection.
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362